Article Details

AstraZeneca's Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation

Retrieved on: 2025-01-19 10:22:10

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation. View article details on hiswai:

Summary

The article discusses epidemiology's role in understanding respiratory diseases, highlighting AstraZeneca's Fasenra (benralizumab) as a breakthrough treatment for COPD. It addresses chronic lower respiratory diseases, emphasizing biologics over traditional inhaler therapies. Tags connect to the concepts of asthma, antiasthmatic drugs, and emerging treatments in respiratory care.

Article found on: www.financialexpress.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up